

6 Literaturverzeichnis

1. Adcock IM. Glucocorticoid-regulated transcription factors. *Pulm Pharmacol Ther* 2001; 14: 211-219.
2. Ahmad M, Medford RM. Evidence for the regulation of Na⁺, K⁺-ATPase α 1 gene expression through the interaction of aldosterone and cAMP-inducible transcriptional factors. *Steroids* 1995; 60: 147-152.
3. Albiston AL, Obeyesekere VR et al. Cloning and tissue distribution of the human 11 β -hydroxysteroid dehydrogenase type 2 enzyme. *Mol Cell Endocrinol* 1994; 105: R11-R17.
4. Alvarez de la Rosa D, Zhang P et al. The serum and glucocorticoid kinase SGK increases the abundance of epithelial sodium channels in the plasma membrane of *Xenopus* oocytes. *J Biol Chem* 1999; 274: 37834-37839.
5. Ammon HPT. Pharmakologie der Nebennierenrindenhormone und analog wirkender Pharmaka. In: Estler CJ (Hrsg.), *Pharmakologie und Toxikologie* (5. Aufl.), Schattauer 2000: 524-543.
6. Amsterdam A, Tajima K, Sasson R. Cell-specific regulation of apoptosis by glucocorticoids: implication to their anti-inflammatory action. *Biochem Pharmacol* 2002; 64: 843-850.
7. Archer TK, Hager GL, Omichinski JG. Sequence-specific DNA binding by glucocorticoid receptor "zinc finger peptides". *Proc Natl Acad Sci U S A* 1990; 87: 7560-7564.
8. Armanini D, Karbowski I, Funder JW. Affinity of liquorice derivatives for mineralocorticoid and glucocorticoid receptors. *Clin Endocrinol (Oxf)* 1983; 19: 609-612.
9. Arriza JL, Weinberger C et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. *Science* 1987; 237: 268-275.
10. Auzou G, Fagart J et al. A single amino acid mutation of Ala-773 in the mineralocorticoid receptor confers agonist properties to 11 β -substituted spiro lactones. *Mol Pharmacol* 2000; 58: 684-691.
11. Avioli LV. Potency ratio - a brief synopsis. *Br J Rheumatol* 1993; 32 Suppl 2: 24-26.
12. Babadjanova G, Allolio B et al. Comparison of the pharmacodynamic effects of deflazacort and prednisolone in healthy subjects. *Eur J Clin Pharmacol* 1996; 51: 53-57.

13. Ballard PL, Carter JP et al. A radioreceptor assay for evaluation of the plasma glucocorticoid activity of natural and synthetic steroids in man. *J Clin Endocrinol Metab* 1975; 41: 290-304.
14. Bamberger CM, Else T et al. Regulation of the human interleukin-2 gene by the α and β isoforms of the glucocorticoid receptor. *Mol Cell Endocrinol* 1997; 136: 23-28.
15. Bamberger CM, Else T et al. Dissociative glucocorticoid activity of medroxy-progesterone acetate in normal human lymphocytes. *J Clin Endocrinol Metab* 1999; 84: 4055-4061.
16. Bamberger CM, Schulte HM, Chrousos GP. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. *Endocr Rev* 1996; 17: 245-261.
17. Bamberger CM, Wald M et al. Inhibition of mineralocorticoid and glucocorticoid receptor function by the heat shock protein 90-binding agent geldanamycin. *Mol Cell Endocrinol* 1997; 131: 233-240.
18. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. *Clin Sci (Lond)* 1998; 94: 557-572.
19. Belvisi MG, Brown TJ et al. New Glucocorticosteroids with an improved therapeutic ratio? *Pulm Pharmacol Ther* 2001; 14: 221-227.
20. Belvisi MG, Wicks SL et al. Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. *J Immunol* 2001; 166: 1975-1982.
21. Berger S, Bleich M et al. Mineralocorticoid receptor knockout mice: lessons on Na^+ metabolism. *Kidney Int* 2000; 57: 1295-1298.
22. Black JW, Leff P. Operational models of pharmacological agonism. *Proc R Soc Lond B Biol Sci* 1983; 220: 141-162.
23. Blackwood EM, Kadonaga JT. Going the distance: a current view of enhancer action. *Science* 1998; 281: 61-63.
24. Bledsoe RK, Montana VG et al. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. *Cell* 2002; 110: 93-105.
25. Boldyreff B, Wehling M. Rapid aldosterone actions: from the membrane to signaling cascades to gene transcription and physiological effects. *J Steroid Biochem Mol Biol* 2003; 85: 375-381.
26. Bujalska I, Shimojo M et al. Human 11β -hydroxysteroid dehydrogenase: studies on the stably transfected isoforms and localization of the type 2 isozyme within renal tissue. *Steroids* 1997; 62: 77-82.

27. Bulens F, Merchiers P et al. Identification of a multihormone responsive enhancer far upstream from the human tissue-type plasminogen activator gene. *J Biol Chem* 1997; 272: 663-671.
28. Bumke-Vogt C, Diederich S et al. Affinities of different steroids to the mineralocorticoid receptor (MR). *Exp Clin Endocrinol Diabetes* 2002; 110 Suppl 1: S47.
29. Buttgerit F, Brand MD, Burmester GR. Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. *Biochem Pharmacol* 1999; 58: 363-368.
30. Buttgerit F, Scheffold A. Rapid glucocorticoid effects on immune cells. *Steroids* 2002; 67: 529-534.
31. Carlstedt-Duke J. Glucocorticoid Receptor β : View II. *Trends Endocrinol Metab* 1999; 10: 339-342.
32. Cartledge S, Lawson N. Aldosterone and renin measurements. *Ann Clin Biochem* 2000; 37: 262-278.
33. Chandler VL, Maler BA, Yamamoto KR. DNA sequences bound specifically by glucocorticoid receptor in vitro render a heterologous promoter hormone responsive in vivo. *Cell* 1983; 33: 489-499.
34. Chen SY, Bhargava A et al. Epithelial sodium channel regulated by aldosterone-induced protein sgk. *Proc Natl Acad Sci U S A* 1999; 96: 2514-2519.
35. Christ M, Wehling M. Rapid actions of aldosterone: lymphocytes, vascular smooth muscle and endothelial cells. *Steroids* 1999; 64: 35-41.
36. Christopoulos A, El Fakahany EE. Qualitative and quantitative assessment of relative agonist efficacy. *Biochem Pharmacol* 1999; 58: 735-748.
37. Clarke WP, Bond RA. The elusive nature of intrinsic efficacy. *Trends Pharmacol Sci* 1998; 19: 270-276.
38. Dahlberg E, Thalen A et al. Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16α , 17α -acetal-substituted glucocorticoids. *Mol Pharmacol* 1984; 25: 70-78.
39. De Bosscher K, Van den Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor- κ B or activator protein-1: molecular mechanisms for gene repression. *Endocr Rev* 2003; 24: 488-522.
40. De Wet JR, Wood KV et al. Cloning of firefly luciferase cDNA and the expression of active luciferase in *Escherichia coli*. *Proc Natl Acad Sci U S A* 1985; 82: 7870-7873.

41. DeFranco DB. Role of molecular chaperones in subnuclear trafficking of glucocorticoid receptors. *Kidney Int* 2000; 57: 1241-1249.
42. Derfoul A, Robertson NM et al. Regulation of the human Na/K-ATPase β 1 gene promoter by mineralocorticoid and glucocorticoid receptors. *J Biol Chem* 1998; 273: 20702-20711.
43. Di Munno O, Imbimbo B et al. Deflazacort versus methylprednisolone in polymyalgia rheumatica: clinical equivalence and relative antiinflammatory potency of different treatment regimens. *J Rheumatol* 1995; 22: 1492-1498.
44. Diamond MI, Miner JN et al. Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. *Science* 1990; 249: 1266-1272.
45. Diederich S, Eigendorff E et al. 11β -hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids. *J Clin Endocrinol Metab* 2002; 87: 5695-5701.
46. Diederich S, Hanke B et al. Metabolism of synthetic corticosteroids by 11β -hydroxysteroid-dehydrogenases in man. *Steroids* 1998; 63: 271-277.
47. Diederich S, Hanke B et al. Metabolism of dexamethasone in the human kidney: nicotinamide adenine dinucleotide-dependent 11β -reduction. *J Clin Endocrinol Metab* 1997; 82: 1598-1602.
48. Diederich S, Quinkler M et al. 11β -Hydroxysteroid-Dehydrogenasen: Schlüssel-Enzyme der Mineralocorticoid- und Glucocorticoid-Wirkung. *Dtsch Med Wochenschr* 1999; 124: 51-55.
49. Drouin J, Sun YL et al. Novel glucocorticoid receptor complex with DNA element of the hormone-repressed POMC gene. *EMBO J* 1993; 12: 145-156.
50. Fagart J, Wurtz JM et al. Antagonism in the human mineralocorticoid receptor. *EMBO J* 1998; 17: 3317-3325.
51. Farman N, Bocchi B. Mineralocorticoid selectivity: molecular and cellular aspects. *Kidney Int* 2000; 57: 1364-1369.
52. Frey FJ, Escher G, Frey BM. Pharmacology of 11β -hydroxysteroid dehydrogenase. *Steroids* 1994; 59: 74-79.
53. Fried J, Borman A. Synthetic Derivatives of Cortical Hormones. *Vitam Horm* 1958; 16: 303-374.
54. Funder JW, Pearce PT et al. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. *Science* 1988; 242: 583-585.

55. Furchgott RF. The use of β -haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. *Adv Drug Res* 1966; 3: 21-55.
56. Gagliardo R, Vignola AM, Mathieu M. Is there a role for glucocorticoid receptor β in asthma? *Respir Res* 2001; 2: 1-4.
57. Gärtner R, Haen E. Nebennierenrindenhormone. In: Forth W, Henschler D et al. (Hrsg.), *Allgemeine und spezielle Pharmakologie* (8. Aufl.), Spektrum Akademischer Verlag 2001: 704-721.
58. Gellersen B, Kempf R et al. Nonpituitary human prolactin gene transcription is independent of Pit-1 and differentially controlled in lymphocytes and in endometrial stroma. *Mol Endocrinol* 1994; 8: 356-373.
59. Giguère V, Hollenberg SM et al. Functional domains of the human glucocorticoid receptor. *Cell* 1986; 46: 645-652.
60. Glass CK. Differential recognition of target genes by nuclear receptor monomers, dimers, and heterodimers. *Endocr Rev* 1994; 15: 391-407.
61. Gold R, Buttgereit F, Toyka KV. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. *J Neuroimmunol* 2001; 117: 1-8.
62. Goldfien A, Morse WI et al. Pharmacological studies in man 11-, 17-, and 21-hydroxy derivatives of progesterone and their fluorinated analogs. *Ann N Y Acad Sci* 1955; 61: 433-441.
63. Gorman CM, Merlino GT et al. The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection. *Proc Natl Acad Sci U S A* 1982; 79: 6777-6781.
64. Haseroth K, Gerdes D et al. Rapid nongenomic effects of aldosterone in mineralocorticoid-receptor-knockout mice. *Biochem Biophys Res Commun* 1999; 266: 257-261.
65. Hellal-Lévy C, Couette B et al. Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors. *FEBS Lett* 1999; 464: 9-13.
66. Hellal-Lévy C, Fagart J et al. Mechanistic aspects of mineralocorticoid receptor activation. *Kidney Int* 2000; 57: 1250-1255.
67. Hench PS, Kendall EC et al. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone, compound E) and of pituitary adrenocorticotrophic hormone on rheumatoid arthritis. *Proc Staff Meet Mayo Clin* 1949; 24: 181-197.

68. Hennebold JD, Daynes RA. Inhibition of skin 11 β -hydroxysteroid dehydrogenase activity in vivo potentiates the anti-inflammatory actions of glucocorticoids. *Arch Dermatol Res* 1998; 290: 413-419.
69. Herzog HL, Nobile A et al. New antiarthritic steroids. *Science* 1955; 121: 176.
70. Hofmann TG, Hehner SP et al. Various glucocorticoids differ in their ability to induce gene expression, apoptosis and to repress NF- κ B-dependent transcription. *FEBS Lett* 1998; 441: 441-446.
71. Hollenberg SM, Giguère V et al. Colocalization of DNA-binding and transcriptional activation functions in the human glucocorticoid receptor. *Cell* 1987; 49: 39-46.
72. Hollenberg SM, Weinberger C et al. Primary structure and expression of a functional human glucocorticoid receptor cDNA. *Nature* 1985; 318: 635-641.
73. Hynes N, van Ooyen AJ et al. Subfragments of the large terminal repeat cause glucocorticoid-responsive expression of mouse mammary tumor virus and of an adjacent gene. *Proc Natl Acad Sci U S A* 1983; 80: 3637-3641.
74. Jaffuel D, Demoly P et al. Transcriptional potencies of inhaled glucocorticoids. *Am J Respir Crit Care Med* 2000; 162: 57-63.
75. Jaffuel D, Roumestan C et al. Correlation between different gene expression assays designed to measure trans-activation potencies of systemic glucocorticoids. *Steroids* 2001; 66: 597-604.
76. Jamieson PM, Chapman KE et al. 11 β -hydroxysteroid dehydrogenase is an exclusive 11 β -reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. *Endocrinology* 1995; 136: 4754-4761.
77. Jefcoate CR, McNamara BC et al. Regulation of cholesterol movement to mitochondrial cytochrome P450_{scc} in steroid hormone synthesis. *J Steroid Biochem Mol Biol* 1992; 43: 751-767.
78. Jensen FC, Girardi AJ et al. Infection of human and simian tissue cultures with Rous Sarcoma Virus. *Proc Natl Acad Sci U S A* 1964; 52: 53-59.
79. Kamynina E, Staub O. Concerted action of ENaC, Nedd4-2, and Sgk1 in transepithelial Na⁺ transport. *Am J Physiol Renal Physiol* 2002; 283: F377-F387.
80. Kauppi B, Jakob C et al. The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. *J Biol Chem* 2003; 278: 22748-22754.
81. Krozowski Z, Li KX et al. The type I and type II 11 β -hydroxysteroid dehydrogenase enzymes. *J Steroid Biochem Mol Biol* 1999; 69: 391-401.

82. Kumar R, Thompson EB. The structure of the nuclear hormone receptors. *Steroids* 1999; 64: 310-319.
83. Lan NC, Graham B et al. Binding of steroids to mineralocorticoid receptors: implications for in vivo occupancy by glucocorticoids. *J Clin Endocrinol Metab* 1982; 54: 332-342.
84. Langhoff E, Ladefoged J. Relative immunosuppressive potency of various corticosteroids measured in vitro. *Eur J Clin Pharmacol* 1983; 25: 459-462.
85. Langhoff E, Olgaard K, Ladefoged J. The immunosuppressive potency in vitro of physiological and synthetic steroids on lymphocyte cultures. *Int J Immunopharmacol* 1987; 9: 469-473.
86. Leckie C, Chapman KE et al. LLC-PK1 cells model 11β -hydroxysteroid dehydrogenase type 2 regulation of glucocorticoid access to renal mineralocorticoid receptors. *Endocrinology* 1995; 136: 5561-5569.
87. Lehn J, Wegmann H. Der Run-Test von Wald und Wolfowitz. In: *Einführung in die Statistik* (2. Aufl.), Teubner 1992: 170-173.
88. Li KX, Obeyesekere VR et al. Oxoreductase and dehydrogenase activities of the human and rat 11β -hydroxysteroid dehydrogenase type 2 enzyme. *Endocrinology* 1997; 138: 2948-2952.
89. Lim-Tio SS, Keightley MC, Fuller PJ. Determinants of specificity of transactivation by the mineralocorticoid or glucocorticoid receptor. *Endocrinology* 1997; 138: 2537-2543.
90. Lingueglia E, Renard S et al. Different homologous subunits of the amiloride-sensitive Na^+ channel are differently regulated by aldosterone. *J Biol Chem* 1994; 269: 13736-13739.
91. Lombès M, Binart N et al. Differential intracellular localization of human mineralocorticosteroid receptor on binding of agonists and antagonists. *Biochem J* 1994; 302: 191-197.
92. Lombès M, Kenouch S et al. The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11β -hydroxysteroid dehydrogenase. *Endocrinology* 1994; 135: 834-840.
93. Lorenz WW, McCann RO et al. Isolation and expression of a cDNA encoding *Renilla reniformis* luciferase. *Proc Natl Acad Sci U S A* 1991; 88: 4438-4442.
94. Losel RM, Falkenstein E et al. Nongenomic steroid action: controversies, questions, and answers. *Physiol Rev* 2003; 83: 965-1016.
95. Luisi BF, Xu WX et al. Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. *Nature* 1991; 352: 497-505.

96. Luzzani F, Glasser A. Differential binding in vitro to glucocorticoid receptors of deflazacort and prednisolone. *Eur J Pharmacol* 1981; 76: 427-430.
97. Mackay D. The mathematics of drug-receptor interactions. *J Pharm Pharmacol* 1966; 18: 201-222.
98. McKenna NJ, O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. *Cell* 2002; 108: 465-474.
99. Meyer T, Carlstedt-Duke J, Starr DB. A weak TATA box is a prerequisite for glucocorticoid-dependent repression of the osteocalcin gene. *J Biol Chem* 1997; 272: 30709-30714.
100. Meyer T, Gustafsson JA, Carlstedt-Duke J. Glucocorticoid-dependent transcriptional repression of the osteocalcin gene by competitive binding at the TATA box. *DNA Cell Biol* 1997; 16: 919-927.
101. Monder C, Stewart PM et al. Licorice inhibits corticosteroid 11 β -dehydrogenase of rat kidney and liver: in vivo and in vitro studies. *Endocrinology* 1989; 125: 1046-1053.
102. Montrella-Waybill M, Clore JN et al. Evidence that high dose cortisol-induced Na⁺ retention in man is not mediated by the mineralocorticoid receptor. *J Clin Endocrinol Metab* 1991; 72: 1060-1066.
103. Morishima Y, Kanelakis KC et al. Evidence for iterative ratcheting of receptor-bound hsp70 between its ATP and ADP conformations during assembly of glucocorticoid receptor hsp90 heterocomplexes. *Biochemistry* 2001; 40: 1109-1116.
104. Möllmann H, Hochhaus G et al. Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. *Pharm Res* 1995; 12: 1096-1100.
105. Naray-Fejes-Toth A, Canessa C et al. Sgk is an aldosterone-induced kinase in the renal collecting duct. Effects on epithelial Na⁺ channels. *J Biol Chem* 1999; 274: 16973-16978.
106. Nathansohn G, Winters G. Impact of structural modifications on the hydrocortisone molecule. *Adv Exp Med Biol* 1984; 171: 1-8.
107. Necela BM, Cidlowski JA. Crystallization of the human glucocorticoid receptor ligand binding domain: a step towards selective glucocorticoids. *Trends Pharmacol Sci* 2003; 24: 58-61.
108. Nelson CC, Hendy SC et al. Determinants of DNA sequence specificity of the androgen, progesterone, and glucocorticoid receptors: evidence for differential steroid receptor response elements. *Mol Endocrinol* 1999; 13: 2090-2107.

109. Oakley RH, Jewell CM et al. The dominant negative activity of the human glucocorticoid receptor β isoform. Specificity and mechanisms of action. *J Biol Chem* 1999; 274: 27857-27866.
110. Oelkers W, Buchen S et al. Impaired renal 11β -oxidation of 9α -fluorocortisol: an explanation for its mineralocorticoid potency. *J Clin Endocrinol Metab* 1994; 78: 928-932.
111. Oelkers W, Diederich S, Bähr V. Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone. *J Clin Endocrinol Metab* 1992; 75: 259-264.
112. Oelkers W, Diederich S, Bähr V. Primary hyperaldosteronism without suppressed renin due to secondary hypertensive kidney damage. *J Clin Endocrinol Metab* 2000; 85: 3266-3270.
113. Papadopoulos V, Widmaier EP et al. In vivo studies on the role of the peripheral benzodiazepine receptor (PBR) in steroidogenesis. *Endocr Res* 1998; 24: 479-487.
114. Pearce D, Matsui W et al. Glucocorticoid receptor transcriptional activity determined by spacing of receptor and nonreceptor DNA sites. *J Biol Chem* 1998; 273: 30081-30085.
115. Pearce D, Yamamoto KR. Mineralocorticoid and glucocorticoid receptor activities distinguished by nonreceptor factors at a composite response element. *Science* 1993; 259: 1161-1165.
116. Pfeiffer R, Beron J, Verrey F. Regulation of Na^+ pump function by aldosterone is α -subunit isoform specific. *J Physiol* 1999; 516: 647-655.
117. Pratt WB, Toft DO. Steroid receptor interactions with heat shock protein and immunophilin chaperones. *Endocr Rev* 1997; 18: 306-360.
118. Prefontaine GG, Walther R et al. Selective binding of steroid hormone receptors to octamer transcription factors determines transcriptional synergism at the mouse mammary tumor virus promoter. *J Biol Chem* 1999; 274: 26713-26719.
119. Quinkler M, Johanssen S et al. Enzyme-mediated protection of the mineralocorticoid receptor against progesterone in the human kidney. *Mol Cell Endocrinol* 2001; 171: 21-24.
120. Quinkler M, Johanssen S et al. Progesterone metabolism in the human kidney and inhibition of 11β -hydroxysteroid dehydrogenase type 2 by progesterone and its metabolites. *J Clin Endocrinol Metab* 1999; 84: 4165-4171.
121. Quinkler M, Meyer B et al. Agonistic and antagonistic properties of progesterone metabolites at the human mineralocorticoid receptor. *Eur J Endocrinol* 2002; 146: 789-799.

122. Quinkler M, Stewart PM. Hypertension and the cortisol-cortisone shuttle. *J Clin Endocrinol Metab* 2003; 88: 2384-2392.
123. Rafestin-Oblin ME, Souque A et al. The severe form of hypertension caused by the activating S810L mutation in the mineralocorticoid receptor is cortisone related. *Endocrinology* 2003; 144: 528-533.
124. Ray DW, Suen CS et al. Structure/function of the human glucocorticoid receptor: tyrosine 735 is important for transactivation. *Mol Endocrinol* 1999; 13: 1855-1863.
125. Raynaud JP, Bouton MM et al. Steroid hormone receptors and pharmacology. *J Steroid Biochem* 1980; 12:143-57.: 143-157.
126. Reichardt HM, Tuckermann JP et al. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. *EMBO J* 2001; 20: 7168-7173.
127. Renard S, Voilley N et al. Localization and regulation by steroids of the α , β and γ subunits of the amiloride-sensitive Na^+ channel in colon, lung and kidney. *Pflugers Arch* 1995; 430: 299-307.
128. Rogerson FM, Dimopoulos N et al. Structural determinants of aldosterone binding selectivity in the mineralocorticoid receptor. *J Biol Chem* 1999; 274: 36305-36311.
129. Rogerson FM, Fuller PJ. Mineralocorticoid action. *Steroids* 2000; 65: 61-73.
130. Rohdewald P, Rehder S, Würthwein G. Rezeptoraffinität synthetischer Glukokortikoide. In: Schulte HM (Hrsg.), Therapie mit Glukokortikoiden (2. Nebennierenkonferenz 1991), Schattauer 1993: 39-50.
131. Rupprecht R, Arriza JL et al. Transactivation and synergistic properties of the mineralocorticoid receptor: relationship to the glucocorticoid receptor. *Mol Endocrinol* 1993; 7: 597-603.
132. Rupprecht R, Reul JM et al. Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. *Eur J Pharmacol* 1993; 247: 145-154.
133. Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. *Pharmacol Ther* 2002; 96: 23-43.
134. Schäcke H, Hennekes H et al. SEGRAs: a novel class of anti-inflammatory compounds. *Ernst Schering Res Found Workshop* 2002; 40: 357-371.
135. Schiatti P, Selva D et al. Antiinflammatory activity and other pharmacological properties of $11\beta,21$ -dihydroxy-2'-methyl-5' β H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione 21-acetate (Deflazacort). *Arzneimittelforschung* 1980; 30: 1543-1549.

136. Schimmer BP, Parker KL. Adrenocorticotrophic Hormone; Adrenocortical Steroids and Their Synthetic Analogs; Inhibitors of the Synthesis and Actions of Adrenocortical Hormones. In: Hardman JG, Limbird LE, Goodman Gilman A (Hrsg.), Goodman and Gilman's The Pharmacological Basis of Therapeutics (10. Aufl.), McGraw-Hill 2001: 1649-1678.
137. Shigaev A, Asher C et al. Regulation of sgk by aldosterone and its effects on the epithelial Na⁺ channel. *Am J Physiol Renal Physiol* 2000; 278: F613-F619.
138. Smith CL, Hager GL. Transcriptional regulation of mammalian genes in vivo. A tale of two templates. *J Biol Chem* 1997; 272: 27493-27496.
139. Smith CL, Htun H et al. Differential activity of progesterone and glucocorticoid receptors on mouse mammary tumor virus templates differing in chromatin structure. *J Biol Chem* 1997; 272: 14227-14235.
140. Smith CL, Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. *Arzneimittelforschung* 1998; 48: 956-960.
141. Souque A, Fagart J et al. The mineralocorticoid activity of progesterone derivatives depends on the nature of the C18 substituent. *Endocrinology* 1995; 136: 5651-5658.
142. Stephenson RP. A modification of receptor theory. *Br J Pharmacol* 1956; 11: 379-393.
143. Stewart PM, Krozowski ZS et al. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 β -hydroxysteroid dehydrogenase type 2 gene. *Lancet* 1996; 347: 88-91.
144. Stewart PM, Murry BA, Mason JJ. Human kidney 11 β -hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned type I isoform. *J Clin Endocrinol Metab* 1994; 79: 480-484.
145. Szapary D, Xu M, Simons SS, Jr. Induction properties of a transiently transfected glucocorticoid-responsive gene vary with glucocorticoid receptor concentration. *J Biol Chem* 1996; 271: 30576-30582.
146. Tannin GM, Agarwal AK et al. The human gene for 11 β -hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. *J Biol Chem* 1991; 266: 16653-16658.
147. Thorn GW, Renold AE et al. Highly potent adrenal cortical steroids: structure and biologic activity. *Ann Intern Med* 1955; 43: 979-1000.
148. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. *Annu Rev Biochem* 1994; 63:451-86.: 451-486.
149. Ugrasbul F, Wiens T et al. Prevalence of mild apparent mineralocorticoid excess in Mennonites. *J Clin Endocrinol Metab* 1999; 84: 4735-4738.

150. Vayssière BM, Dupont S et al. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. *Mol Endocrinol* 1997; 11: 1245-1255.
151. Vottero A, Chrousos GP. Glucocorticoid Receptor β : View I. *Trends Endocrinol Metab* 1999; 10: 333-338.
152. Warriar N, Page N, Govindan MV. Transcription activation of mouse mammary tumor virus-chloramphenicol acetyltransferase: a model to study the metabolism of cortisol. *Biochemistry* 1994; 33: 12837-12843.
153. Weinberger C, Hollenberg SM et al. Identification of human glucocorticoid receptor complementary DNA clones by epitope selection. *Science* 1985; 228: 740-742.
154. Weiss JM, Morgan PH et al. The cubic ternary complex receptor-occupancy model. III. resurrecting efficacy. *J Theor Biol* 1996; 181: 381-397.
155. White PC. Genetic diseases of steroid metabolism. *Vitam Horm* 1994; 49: 131-195.
156. Whorwood CB, Ricketts ML, Stewart PM. Regulation of sodium-potassium adenosine triphosphate subunit gene expression by corticosteroids and 11β -hydroxysteroid dehydrogenase activity. *Endocrinology* 1994; 135: 901-910.
157. Wilson RC, Harbison MD et al. Several homozygous mutations in the gene for 11β -hydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess. *J Clin Endocrinol Metab* 1995; 80: 3145-3150.
158. Wulff P, Vallon V et al. Impaired renal Na^+ retention in the *sgk1*-knockout mouse. *J Clin Invest* 2002; 110: 1263-1268.
159. Zhang XK, Dong JM, Chiu JF. Regulation of α -fetoprotein gene expression by antagonism between AP-1 and the glucocorticoid receptor at their overlapping binding site. *J Biol Chem* 1991; 266: 8248-8254.